Table 2.
Summary of results from the systematic review on the association between diabetes and incident AD. Interacting factors with diabetes are also included.
| Article | Study Name | Sample Size | Number of Incident AD Cases | Years of Follow Up | Risk Factor | Interactions | OR/RR/HR | 95% Confidence Interval | P value |
|---|---|---|---|---|---|---|---|---|---|
| Hayden/200620 | CCSMHA | 3264 | 104 | Max: 5 | diabetes | not analyzed | 1.33 | 0.66–2.46 | n.s. |
| Akomolafe/200636 | Framingham | 2210 | 237 | 12.7 | diabetes | not analyzed | 1.15 | 0.65–2.05 | n.s. |
| Borenstein/200535 | Kame Project | 1859 | 90 | Max: 9 | diabetes | not analyzed | not given | not given | 0.35 |
| Xu/200434 | Kungsholmen Project | 1301 | 260 | Max: 6 | diabetes | not analyzed | 1.3 | 0.9–2.1 | n.s. |
| Lindsay/200223 | CSHA | 4615 | 194 | Max: 5 | diabetes | not analyzed | 1.03 | 0.58–1.84 | n.s. |
| MacKnight/200238 | CSHA | 5574 | 267 | Max: 5 | diabetes | not analyzed | 1.3 | 0.83–2.03 | n.s. |
| Posner/200226 | WHICAP | 1259 | 157 | Max: 7 | diabetes | not analyzed | 1.3 | 0.7–2.6 | n.s. |
| Luchsinger/200137 | WHICAP | 1262 | 157 | 4.3 | diabetes | not analyzed | 1.3 | 0.8–1.9 | n.s. |
| Tyas/200127 | MSHA | 694 | 36 | Max: 5 | diabetes | not analyzed | 2.7 | 0.85–8.52 | n.s. |
| Arvanitakis/200439 | Religious Orders Study | 824 | 151 | 5.5 | diabetes | not analyzed | 1.65 | 1.10–2.47 | not given |
| Xu/200733 | Kungsholmen Project | 1173 | 307 | Max: 9 | borderline diabetes | not analyzed | 1.77 | 1.06–2.97 | not given |
| Peila/200240 | HHP/HAAS | 2574 | 76 | 2.91 | diabetes, type 2 | not analyzed | 1.9 | 1.1–3.2 | not given |
| Honig/200332 | WHICAP | 1766 | 181 | Max: 7 | diabetes | stroke | 4.12 | 2.35–7.23 | not given |
| Luchsinger/200528 | WHICAP | 1138 | 176 | 5.5 | diabetes | hypertension | 3.3 | 1.9–5.9 | 0.03 |
| Xu/200733 | Kungsholmen Project | 1173 | 307 | Max: 9 | borderline diabetes | severe systolic hypertension (≥180 mm Hg) | 4.89 | 1.07–22.42 | 0.04 |
| Xu/200434 | Kungsholmen Project | 1301 | 260 | Max: 6 | diabetes | severe systolic hypertension (≥180 mm Hg) | 2.6 | 1.0–6.8 | 0.05 |
| Borenstein/200535 | Kame Project | 1859 | 90 | Max: 9 | diabetes | APOE ε4 non carriers | 2.68 | 1.20–6.00 | 0.02 |
| Borenstein/200535 | Kame Project | 1859 | 90 | Max: 9 | diabetes | APOE ε4 carriers | 0.45 | 0.11–1.96 | 0.29 |
| Xu/200733 | Kungsholmen Project | 1173 | 307 | Max: 9 | borderline diabetes | APOE-ε4 | not given | not given | n.s. |
| Xu/200434 | Kungsholmen Project | 1301 | 260 | Max: 6 | diabetes | APOE ε4 carriers | 1 | 0.3–2.9 | n.s. |
| Peila/200240 | HHP/HAAS | 2574 | 76 | 2.91 | diabetes, type 2 | APOE ε4 | not given | not given | p>0.2 |
AD-Alzheimer disease; OR-odds ratio; RR-relative risk; HR-hazard ratio; CCSMHA-Cache County Study of Memory, Health, and Aging; CSHA-Canadian Study of Health and Aging; WHICAP-Washington Heights-Inwood Columbia Aging Project; MSHA-Manitoba Study of Health and Aging; HHP/HAAS-Honolulu Heart Program/Honolulu- Asia Aging Study